About Genomenon, Inc

Genomenon develops the Mastermind Genomic Intelligence Platform, which utilizes AI to analyze and interpret extensive genomic datasets, providing actionable insights for clinical diagnostics and precision therapeutics. The platform enhances variant interpretation efficiency, enabling healthcare professionals to make informed decisions based on a comprehensive database of over 26 million curated genomic variants.

<problem> Interpreting the vast amount of genomic data produced by next-generation sequencing (NGS) is a significant bottleneck in clinical diagnostics and precision medicine. Identifying relevant variants and understanding their clinical significance requires extensive manual curation and analysis of scientific literature, which is time-consuming and can lead to delays in diagnosis and treatment. </problem> <solution> Genomenon's Mastermind Genomic Intelligence Platform uses artificial intelligence to analyze and interpret genomic datasets, providing clinicians and researchers with actionable insights. The platform indexes and curates a comprehensive database of genomic variants and their associated scientific evidence, enabling rapid search and retrieval of relevant information. By automating the variant interpretation process, Mastermind accelerates diagnosis, informs treatment decisions, and facilitates the development of precision therapeutics. The platform also offers a Cancer Knowledgebase (CKB) to interpret cancer variants, connecting them to therapies and clinical trials. </solution> <features> - AI-powered analysis of over 26 million genomic variants and their associated scientific literature - Rapid search and filtering capabilities to identify relevant variants based on gene, disease, and other criteria - Comprehensive database of gene-disease associations and variant data, constantly updated with new research - Cancer Knowledgebase (CKB) for interpreting cancer variants and connecting them to therapies and clinical trials - Integration with tertiary analytic platforms via API or flat files - On-demand evidence curation and variant classification services - Germline and somatic variant interpretation platforms </features> <target_audience> The primary users are clinical geneticists, molecular pathologists, oncologists, and researchers involved in clinical diagnostics, precision medicine, and drug development. </target_audience>

What does Genomenon, Inc do?

When was Genomenon, Inc founded?

Genomenon, Inc was founded in 2014.

How much funding has Genomenon, Inc raised?

Genomenon, Inc has raised 5500000.

Founded

2014

Funding

5500000

Employees

139 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Genomenon, Inc

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

genomenon.com 7K+

Crunchbase

Founded 2014

Funding

Estimated Funding

$5M+

Team (100+)

No team information available.

Company Description

Problem

Interpreting the vast amount of genomic data produced by next-generation sequencing (NGS) is a significant bottleneck in clinical diagnostics and precision medicine. Identifying relevant variants and understanding their clinical significance requires extensive manual curation and analysis of scientific literature, which is time-consuming and can lead to delays in diagnosis and treatment.

Solution

Genomenon's Mastermind Genomic Intelligence Platform uses artificial intelligence to analyze and interpret genomic datasets, providing clinicians and researchers with actionable insights. The platform indexes and curates a comprehensive database of genomic variants and their associated scientific evidence, enabling rapid search and retrieval of relevant information. By automating the variant interpretation process, Mastermind accelerates diagnosis, informs treatment decisions, and facilitates the development of precision therapeutics. The platform also offers a Cancer Knowledgebase (CKB) to interpret cancer variants, connecting them to therapies and clinical trials.

Features

AI-powered analysis of over 26 million genomic variants and their associated scientific literature

Rapid search and filtering capabilities to identify relevant variants based on gene, disease, and other criteria

Comprehensive database of gene-disease associations and variant data, constantly updated with new research

Cancer Knowledgebase (CKB) for interpreting cancer variants and connecting them to therapies and clinical trials

Integration with tertiary analytic platforms via API or flat files

On-demand evidence curation and variant classification services

Germline and somatic variant interpretation platforms

Target Audience

The primary users are clinical geneticists, molecular pathologists, oncologists, and researchers involved in clinical diagnostics, precision medicine, and drug development.